DRUGS FOR PHOTODYNAMIC THERAPY

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。目前正在合成和表征用于光动力疗法的合作研究项目的酞菁和萘酞菁类化合物。这项工作的重点是合成具有所需的光吸收、溶解性、极性和稳定性的化合物。制成的化合物通过光谱学进行表征，然后用于细胞和动物的合作研究。这项工作已经产生了一种名为Pc4的药物，该药物已被批准用于癌症患者的第一阶段人体临床试验

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Compounds of the phthalocyanine and napthalocyanine types are being synthesized and characterized for use in a cooperative research program on photodynamic therapy. The work is focused on the synthesis of compounds that have the desired light absorption, solubility, polarity, and stability. The compounds made are characterized by spectroscopy and then used in collaborative cell and animal studies. The work has resulted in a drug, Pc 4, which has been approved for use in Phase 1 human clinical trials with cancer patients